Meeting
2021 ASCO Annual Meeting
A phase 1 dose-escalation study of intravenously (IV) administered TAK-676, a novel STING agonist, alone and in combination with pembrolizumab in patients (pts) with advanced or metastatic solid tumors.
Presenter
Gerald Steven Falchook, MD
Sarah Cannon Research Institute at HealthONE
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Clinical Trial Registration Number
NCT04420884
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS2670)
DOI
10.1200/JCO.2021.39.15_suppl.TPS2670
Abstract #
TPS2670
Poster Bd #
Online Only
Abstract Disclosures
Similar Videos & Slides
Speaker: Panel Discussion
Videos & Slides
2022 ASCO Annual Meeting
Interim safety and efficacy results from AURELIO-03: A phase 1 dose escalation study of the IL-2/IL-15 receptor βγ superagonist SOT101 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.
Speaker: Elena Garralda, MD, MSc
Videos & Slides
2021 ASCO Annual Meeting
PF‑06939999, a potent and selective PRMT5 inhibitor, in patients with advanced or metastatic solid tumors: A phase 1 dose escalation study.
Speaker: Jordi Rodon Ahnert, PhD, MD
Speaker: Charles J. Ryan, MD